Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Forte Biosciences, Inc.

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provided a general business update. 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of an aggregate of 1,614,035... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences Announces Proposed Public Offering of Common Stock
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the clinical trial of FB-401 for the... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (NASDAQ: FBRX) (www.fortebiorx.com), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update
Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market... 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces Issuance of New U.S. Patent
FORTE BIOSCIENCES, INC. ANNOUNCES ISSUANCE OF NEW U.S. PATENT 
Tickers FBRX
From Business Wire News Releases
Forte Biosciences, Inc. Announces Closing of Merger With Tocagen
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced merger with Tocagen Inc. (previously trading on NASDAQ under... 
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.